Papers | The Initiative on Enabling Choice and Competition in Health Care

Beyond Pigou: externalities and civil society in the supply–demand framework | May 2023

by susuguo | May 2, 2023

The extent of voluntary cooperation in the presence of externalities is shown as an equilib- rium outcome in the supply and demand framework. The analysis uses familiar ingredients to provide a new way of understanding the results of the extensive literature beginning...

Policy Brief: The Impact of the Inflation Reduction Act on Generic and Biosimilar Competition | December 2022

by sfrazee | Dec 23, 2022

This Policy Brief analyzes the impact of The Inflation Reduction Act (IRA) on generic and biosimilar competition. We first review the large savings that generic and biosimilar competition entails in the U.S., which is threatened by competitors’ uncertain investments....

The Value of Innovation Delaying the Progression of Alzheimer’s Disease in the US | November 2022

by mheinl | Nov 28, 2022

Despite the large disease burden imposed by Alzheimer’s disease (AD), little quantitative evidence exists on the aggregate value stemming from innovation slowing the progression of the disease. To fill this gap, this paper uses the existing evidence base to assess the...

Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation | November 2022

by mheinl | Nov 1, 2022

This paper revisits Peltzman (1973) in light of two recent opportunities to quantitatively assess tradeoffs in drug regulation. First, reduced regulatory barriers to drug manufacturing associated with the 2017 reauthorization of Generic Drug User Fee Amendments were...

The Value of Home Administrated over Physician-Administered Alzheimer’s Treatments | October 2022

by sfrazee | Oct 26, 2022

This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion...

« Older Entries

Next Entries »

Beyond Pigou: externalities and civil society in the supply–demand framework | May 2023

Policy Brief: The Impact of the Inflation Reduction Act on Generic and Biosimilar Competition | December 2022

The Value of Innovation Delaying the Progression of Alzheimer’s Disease in the US | November 2022

Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation | November 2022

The Value of Home Administrated over Physician-Administered Alzheimer’s Treatments | October 2022

Recent Posts